Equillium Inc (EQ)

Currency in USD
2.260
+0.050(+2.26%)
Closed·
2.2600.000(0.00%)
·
EQ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.2002.390
52 wk Range
0.2702.700
Key Statistics
Prev. Close
2.21
Open
2.23
Day's Range
2.2-2.39
52 wk Range
0.27-2.7
Volume
467.27K
Average Volume (3m)
426.69K
1-Year Change
470.7071%
Book Value / Share
0.94
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EQ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.375
Upside
+182.08%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

Equillium Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.375
(+182.08% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Oppenheimer
Buy7.00+209.73%-New CoverageApr 23, 2026
B.Riley
Buy6.00+165.49%-New CoverageApr 16, 2026
Raymond James
Buy6.00+165.49%-New CoverageApr 13, 2026
Cantor Fitzgerald
Buy---New CoverageApr 07, 2026
Roth/MKM
Buy12.00+430.97%-New CoverageMar 13, 2026

Earnings

Latest Release
May 13, 2026
EPS / Forecast
-0.06 / -0.05
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

EQ Income Statement

Compare EQ to Peers and Sector

Metrics to compare
EQ
Peers
Sector
Relationship
P/E Ratio
−7.5x−32.6x−0.5x
PEG Ratio
−0.22−0.400.00
Price/Book
2.4x10.3x2.6x
Price / LTM Sales
-6.8x3.1x
Upside (Analyst Target)
184.4%51.3%53.0%
Fair Value Upside
Unlock−3.1%6.3%Unlock

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.66M7.37%10.30M
Other Institutional Investors
59.36M92.63%131.19M
Public Companies & Retail Investors
0.000.00%0.00
Total
64.02M100.00%141.49M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Janus Henderson Group plc9.62%6,083,23913,444
ADAR1 Capital Management, LLC8.87%5,608,07812,394

People Also Watch

1.100
QNCX
+2.80%
4.53
MGNX
+6.84%
74.52
PKX
+0.22%
2.610
IFRX
+5.67%
4.1600
TYGO
+4.52%

FAQ

What Is the Equillium (EQ) Stock Price Today?

The Equillium stock price today is 2.260 USD.

What Stock Exchange Does Equillium Trade On?

Equillium is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Equillium?

The stock symbol for Equillium is "EQ."

What Is the Equillium Market Cap?

As of today, Equillium market cap is 140.360M USD.

What Is Equillium's Earnings Per Share (TTM)?

The Equillium EPS (TTM) is -0.271.

When Is the Next Equillium Earnings Date?

Equillium will release its next earnings report on Aug 12, 2026.

From a Technical Analysis Perspective, Is EQ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Equillium Stock Split?

Equillium has split 1 times.

How Many Employees Does Equillium Have?

Equillium has 15 employees.

What is the current trading status of Equillium (EQ)?

As of May 22, 2026, Equillium (EQ) is trading at a price of 2.260 USD, with a previous close of 2.210 USD. The stock has fluctuated within a day range of 2.200 USD to 2.390 USD, while its 52-week range spans from 0.270 USD to 2.700 USD.

What Is Equillium (EQ) Price Target According to Analysts?

The average 12-month price target for Equillium is 6.375 USD, with a high estimate of 12 USD and a low estimate of 1 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +182.08% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.